Use of Intravenous Immunoglobulin in Severe Covid 19 Infection - A Potential Game Changer

Authors

  •   Ravi Kumar ICU and Critical Care Services, Sagar Hospital, Bangalore, Karnataka
  •   P. Vignesh ICU and Critical Care Services, Sagar Hospital, Bangalore, Karnataka
  •   Jagadish Chandra ICU and Critical Care Services, Sagar Hospital, Bangalore, Karnataka
  •   Pratyush Miglani ICU and Critical Care Services, Sagar Hospital, Bangalore, Karnataka

DOI:

https://doi.org/10.4103/kaj/2020/v18i3-4/167847

Keywords:

Immunomodulation, Immunomodulators, Severe Covid 19, IVIG

Abstract

The novel Coronavirus has emerged as one of the deadliest pandemics in human history. India is facing challenges of uncontrolled proportions of new cases/death toll, highly virulent variants of Coronavirus and limited therapeutic options. The disease spectrum has mild, moderate and severe stages. Complications like SIRS, cytokine storm, ARDS and MODS are seen at severe stage and hence this stage remains a crucial target to reduce hospital stay and mortality. Immunomodulation is the cornerstone in treating hyperimmune response during severe stage. Though there are various upcoming immunomodulators, there is uncertainty about the efficacy of each. Search for the best innovative therapeutic option continues. In this context, Intravenous Immunoglobulin (IVIG) is one of the potential interventions with a unique feature of pleiotropic immunomodulating actions. In this case series, we describe two cases who were in severe stage of Covid-19 infection and didn’t respond to any conventional antiviral and immunomodulators. IVIG was administered to both. It was found that there was remarkable improvement in patient’s condition. Both the patients recovered clinically and were discharged from hospital. Hence, IVIG can be considered as a potential therapeutic strategy in severe Covid-19 infection.

Downloads

Download data is not yet available.

Downloads

Published

2020-12-17

How to Cite

Kumar, R., Vignesh, P., Chandra, J., & Miglani, P. (2020). Use of Intravenous Immunoglobulin in Severe Covid 19 Infection - A Potential Game Changer. Karnataka Anaesthesia Journal, 18(3-4), 75–83. https://doi.org/10.4103/kaj/2020/v18i3-4/167847

Issue

Volume 18, Issue 3-4, July-December 2020

Section

Case Reports
Crossref
Scopus
Google Scholar
Europe PMC

References

Meyerowitz EA, Sen P, Schoenfeld SR, Neilan TG, Frigault MJ, Stone JH, et al. Immunomodulation as treatment for Severe Coronavirus disease 2019: A systematic review of current modalities and future directions. Clinical Infectious Diseases. 2021; 72(12). https://doi.org/10.1093/cid/ciaa1759. PMid:33216852. PMCid:PMC7717185

Zhang Y, Chen Y, Meng Z. Immunomodulation for severe COVID-19 pneumonia: The state of the art. Frontiers in Immunology. 2020. https://doi.org/10.3389/fimmu.2020.577442. PMid:33240265. PMCid:PMC7680845

Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Pharmaco-immunomodulatory therapy in COVID-19. Drugs. 2020; 80(13):1267–92. ht tps://doi.org/10.1007/s40265-020-01367-z. PMid:32696108. PMCid:PMC7372203

Tzilas V, Manali E, Papiris S, Bouros D. Intravenous immunoglobulin for the treatment of COVID19: A promising tool. Respiration. 2020; 99(12):1087–9. https://doi.org/10.1159/000512727. PMid:33212437. PMCid:PMC7801989

Gharebaghi N, Nejadrahim R, Mousavi SJ, Sadat-Ebrahimi S-R, Hajizadeh R. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. BMC Infectious Diseases. 2020; 20(1):786. https://doi.org/10.1186/s12879-020-05507-4. PMid:33087047. PMCid:PMC7576972

Raman RS, Bhagwan Barge V, Anil Kumar D, Dandu H, Rakesh Kartha R, Bafna V, et al. A Phase II safety and efficacy study on prognosis of moderate pneumonia in Coronavirus Disease 2019 patients with regular intravenous immunoglobulin therapy. The Journal of Infectious Diseases. 2021; 223(9):1538–43. https://doi.org/10.1093/ infdis/jiab098. PMid:33585890. PMCid:PMC7928808

Nguyen AA, Habiballah SB, Platt CD, Geha RS, Chou JS, McDonald DR. Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution! Clinical immunology (Orlando, Fla.). 2020; 216. https://doi.org/10.1016/j.clim.2020.108459. PMid:32418917. PMCid:PMC7211658

Cao W, Liu X, Bai T, Fan H, Hong K, Song H, et al. Highdose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease 2019. Open Forum Infectious Diseases. 2020; 7(3). https://doi.org/10.1093/ofid/ofaa102. PMid:32258207. PMCid:PMC7111600

Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, et al. Update on the use of immunoglobulin in human disease: A review of evidence. Journal of Allergy and Clinical Immunology. 2017; 139(3S):S1–46. https://doi.org/10.1016/j.jaci.2016.09.023. PMid:28041678

Nabih HK. Importance of immunoglobulin therapy for COVID-19 patients with lymphocytopenia. Bulletin of the National Research Centre. 2021; 45(1):46. https://doi.org/10.1186/s42269-021-00502-4. PMid:33642851. PMCid:PMC7897881

Dourmishev LA, Guleva DV, Miteva LG. Intravenous immunoglobulins: Mode of action and indications in autoimmune and inflammatory dermatoses. International Journal of Inflammation. 2016; 2016. https://doi.org/10.1155/2016/3523057. PMid:26885437. PMCid:PMC4739470

Jacob S, Rajabally YA. Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Current Neuropharmacology. 2009; 7(4):337–42. https: //doi.org/10.2174/157015909790031166. PMid:20514213. PMCid:PMC2811867

Hartung H-P. Advances in the understanding of the mechanism of action of IVIg. Journal of Neurology. 2008; 255 Suppl 3:3–6. https://doi.org/10.1007/s00415-008-3002-0. PMid:18685919